தலை மருத்துவ புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலை மருத்துவ புற்றுநோயியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலை மருத்துவ புற்றுநோயியல் Today - Breaking & Trending Today

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients
The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumor has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumor converted to HER2-low expression in the recurrent tumor possibly offering an option to such hard-to-treat tumors. ....

Comunidad Autonoma De Cataluna , Aleix Prat , Emily Henderson , School Of Oncology , University Of Padua , Cancer Virtual Congress , Federica Miglietta , Professor Aleix Prat , Head Medical Oncology , Hospital Clinic , காமுனிடட தன்னாட்சி டி கடலுள் , எமிலி ஹென்டர்சன் , பள்ளி ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் ப்யாட்யூவ , தலை மருத்துவ புற்றுநோயியல் , மருத்துவமனை சிகிச்சையகம் ,

Switch of breast tumors to HER2-low might provide greater therapeutic options

Switch of breast tumors to HER2-low might provide greater therapeutic options
ANI |
Updated: May 09, 2021 18:56 IST
Lugano [Switzerland], May 9 (ANI): The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. The study was published in the journal Annals of Oncology. ....

Italy General , Comunidad Autonoma De Cataluna , Aleix Prat , School Of Oncology , University Of Padua , Cancer Virtual Congress , Professor Aleix Prat , Head Medical Oncology , Hospital Clinic , இத்தாலி ஜநரல் , காமுனிடட தன்னாட்சி டி கடலுள் , பள்ளி ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் ப்யாட்யூவ , தலை மருத்துவ புற்றுநோயியல் , மருத்துவமனை சிகிச்சையகம் ,

Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options

European Society for Medical Oncology
The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours.
The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumour converted to HER2-low expression in the recurrent tumour possibly offering an option to such hard-to-treat tumours. ....

Comunidad Autonoma De Cataluna , Aleix Prat , School Of Oncology , University Of Padua , Cancer Virtual Congress , Professor Aleix Prat , Head Medical Oncology , Hospital Clinic , காமுனிடட தன்னாட்சி டி கடலுள் , பள்ளி ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் ப்யாட்யூவ , தலை மருத்துவ புற்றுநோயியல் , மருத்துவமனை சிகிச்சையகம் ,

'Cancer mortality rate can be halved with early detection'

‘Cancer mortality rate can be halved with early detection’
Updated:
Updated:
Share Article
AAA
Cancer mortality rate can be halved with early detection. Only when cancer is diagnosed after the disease advances to terminal stage, many patients die. The success rate of treatments for all forms of cancer is increasing – in some cases up to 99%, according to medical experts of Meenakshi Mission Hospital and Research Centre here.
Addressing the media on Wednesday ahead of World Cancer Day that falls on February 4, the medical experts said the country could reduce cancer deaths by popularising preventive health check-ups and investing in medical infrastructure for comprehensive early detection and treatment. They stressed the need for a balanced diet, an active lifestyle and avoiding smoking, tobacco chewing and alcohol consumption. ....

Krishnakumar Rathnam , Head Of The Department Oncology Dr , Meenakshi Mission Hospital , Research Centre , World Cancer Day , Department Oncology , Head Medical Oncology , Head Surgical Oncology , Radiation Oncology , கிருஷ்ணகுமார் ரத்னம் , தலை ஆஃப் தி துறை புற்றுநோயியல் டாக்டர் , மீனாட்சி பணி மருத்துவமனை , ஆராய்ச்சி மையம் , உலகம் புற்றுநோய் நாள் , துறை புற்றுநோயியல் , தலை மருத்துவ புற்றுநோயியல் , தலை அறுவை சிகிச்சை புற்றுநோயியல் , கதிர்வீச்சு புற்றுநோயியல் ,